Dissecting the heterogeneity of triple-negative breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 15, 2012, Pages 1879-1887

  Metzger Filho, Otto ^a   Tutt, Andrew ^b   De Azambuja, Evandro ^a   Saini, Kamal S ^a   Viale, Giuseppe ^e   Loi, Sherene ^a   Bradbury, Ian ^d   Bliss, Judith M ^c   Azim, Hatem A ^a   Ellis, Paul ^b   Di Leo, Angelo ^f   Baselga, José ^g   Sotiriou, Christos ^a   Piccart Gebhart, Martine ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d FRONTIER SCIENCE SCOTLAND LTD   (United Kingdom)

^e UNIVERSITY OF MILAN   (Italy)

^f Hospital of Prato   (Italy)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BMN 673; BSI 401; CAPECITABINE; CARBOPLATIN; CEP 9722; CETUXIMAB; CISPLATIN; CLAUDIN; CO 338; CYCLOPHOSPHAMIDE; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 6; DOCETAXEL; DOXORUBICIN; E 7016; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; INIPARIB; INO 1001; IXABEPILONE; METHOTREXATE; NIRAPARIB; OLAPARIB; PACLITAXEL; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL JUNCTION; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL PRACTICE; DISEASE FREE SURVIVAL; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DRUG DOSE REDUCTION; EXCISION REPAIR; FATIGUE; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPOPHOSPHATEMIA; IMMUNOREGULATION; IN VITRO STUDY; MONOTHERAPY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; UPREGULATION; VISCERAL METASTASIS;

EID: 84863994288     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.2010     Document Type: Review

References (126)

1. Bauer KR, Brown M, Cress RD, et al: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California Cancer Registry. Cancer 109: 1721-1728, 2007 (Pubitemid 46668532)
2. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502, 2006 (Pubitemid 43854964)
3. Morris GJ, Naidu S, Topham AK, et al: Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: A single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 110:876-884, 2007 (Pubitemid 47257667)
4. Stead LA, Lash TL, Sobieraj JE, et al: Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res 11:R18, 2009
5. Lund MJ, Trivers KF, Porter PL, et al: Race and triple negative threats to breast cancer survival: A population-based study in Atlanta, GA. Breast Cancer Res Treat 113:357-370, 2009
6. Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434, 2007 (Pubitemid 47219710)
7. Anders CK, Fan C, Parker JS, et al: Breast carcinomas arising at a young age: Unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol 29:e18-e20, 2011
8. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000
9. Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281, 2008
10. Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374, 2004 (Pubitemid 39100473)
11. Cancello G, Maisonneuve P, Rotmensz N, et al: Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol 21:1974-1981, 2010
12. Dent R, Hanna WM, Trudeau M, et al: Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115:423-428, 2009
13. Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al: Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 12:1533-1539, 2006
14. Metzger O, Sun Z, Viale G, et al: Patterns of breast cancer relapse according to breast cancer subtypes in lymph node-negative breast cancer: Results from International Breast Cancer Study Group trials VIII and IX. Cancer Res 70:24s, 2010 (suppl; abstr P5-13-01)
15. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18-43, 2007 (Pubitemid 46174133)
16. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795, 2010
17. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001 (Pubitemid 32878711)
18. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423, 2003 (Pubitemid 36842560)
19. Calza S, Hall P, Auer G, et al: Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 8:R34, 2006
20. Ihemelandu CU, Leffall LD Jr, Dewitty RL, et al: Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome. Ann Surg Oncol 14:2994-3003, 2007 (Pubitemid 47460642)
21. Hu Z, Fan C, Oh DS, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7:96, 2006
22. Yu K, Lee CH, Tan PH, et al: Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res 10:5508-5517, 2004 (Pubitemid 39100489)
23. Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100:10393-10398, 2003 (Pubitemid 37071889)
24. Rakha EA, El-Sayed ME, Green AR, et al: Breast carcinoma with basal differentiation: A proposal for pathology definition based on basal cytokeratin expression. Histopathology 50:434-438, 2007 (Pubitemid 46328193)
25. Livasy CA, Karaca G, Nanda R, et al: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19:264-271, 2006 (Pubitemid 43117611)
26. Rakha EA, Elsheikh SE, Aleskandarany MA, et al: Triple-negative breast cancer: Distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15:2302-2310, 2009
27. Moinfar F: Is 'basal-like' carcinoma of the breast a distinct clinicopathological entity? A critical review with cautionary notes. Pathobiology 75:119-131, 2008
28. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, et al: Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 9:R16, 2007
29. Kim MJ, Ro JY, Ahn SH, et al: Clinicopathologic significance of the basal-like subtype of breast cancer: A comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37:1217-1226, 2006 (Pubitemid 44286991)
30. Potemski P, Kusinska R, Watala C, et al: Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology 69:478-485, 2005
31. Fulford LG, Reis-Filho JS, Ryder K, et al: Basal-like grade III invasive ductal carcinoma of the breast: Patterns of metastasis and long-term survival. Breast Cancer Res 9:R4, 2007
32. Fulford LG, Easton DF, Reis-Filho JS, et al: Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 49:22-34, 2006 (Pubitemid 43972917)
33. Jacquemier J, Padovani L, Rabayrol L, et al: Typical medullary breast carcinomas have a basal/ myoepithelial phenotype. J Pathol 207:260-268, 2005 (Pubitemid 41556449)
34. Bertucci F, Finetti P, Cervera N, et al: Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 66:4636-4644, 2006
35. Rodriguez-Pinilla SM, Rodriguez-Gil Y, Moreno-Bueno G, et al: Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: An immunohistochemical and gene amplification study. Am J Surg Pathol 31:501-508, 2007 (Pubitemid 46569033)
36. Huober JB, Gelber S, Thürlimann B, et al: Prognosis of medullary breast cancer: Analyses of 13 International Breast Cancer Study Group (IBCSG) trials. J Clin Oncol 28:99s, 2010 (suppl; abstr 630)
37. Ellis P, Schnitt SJ, Sastre-Garau X, et al: Invasive breast carcinoma, in Tavassoli FA, Devilee P (eds): WHO Classification of Tumours Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France, IARC Press, 2003
38. McClenathan JH, de la Roza G: Adenoid cystic breast cancer. Am J Surg 183:646-649, 2002 (Pubitemid 34722530)
39. Weigelt B, Horlings HM, Kreike B, et al: Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 216:141-150, 2008
40. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002 (Pubitemid 34130608)
41. Foulkes WD, Stefansson IM, Chappuis PO, et al: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482-1485, 2003 (Pubitemid 37279334)
42. Arnes JB, Brunet JS, Stefansson I, et al: Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 11:4003-4011, 2005 (Pubitemid 40791563)
43. Laakso M, Loman N, Borg A, et al: Cytokeratin 5/14-positive breast cancer: True basal phenotype confined to BRCA1 tumors. Mod Pathol 18: 1321-1328, 2005 (Pubitemid 41348650)
44. Lakhani SR, Reis-Filho JS, Fulford L, et al: Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11:5175-5180, 2005 (Pubitemid 41003703)
45. Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases - Breast Cancer Linkage Consortium. Lancet 349:1505-1510, 1997
46. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004 (Pubitemid 40051905)
47. Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med 360:790-800, 2009
48. Desmedt C, Haibe-Kains B, Wirapati P, et al: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158-5165, 2008
49. Lehmann BD, Bauer JA, Chen X, et al: Transcriptome analysis of triple negative breast cancers identifies six distinct biological subgroups and reveals therapeutic strategies. Cancer Res 70:24s, 2010 (suppl; abstr PD01-07)
50. Prat A, Parker JS, Karginova O, et al: Phenotypic and molecular characterization of the claudinlow intrinsic subtype of breast cancer. Breast Cancer Res 12:R68, 2010
51. Lim E, Vaillant F, Wu D, et al: Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15:907-913, 2009
52. Prat A, Perou CM: Mammary development meets cancer genomics. Nat Med 15:842-844, 2009
53. Rodriguez AA, Makris A, Wu MF, et al: DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat 123:189-196, 2010
54. Teschendorff AE, Miremadi A, Pinder SE, et al: An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8:R157, 2007
55. Yau C, Esserman L, Moore DH, et al: A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res 12:R85, 2010
56. Rody A, Karn T, Liedtke C, et al: Identification of a clinically relevant gene signature in triple negative and basal-like breast cancer. Cancer Res 70:24s, 2010 (suppl; abstr S5-5)
57. Denkert C, Loibl S, Noske A, et al: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105-113, 2010
58. Farmer P, Bonnefoi H, Anderle P, et al: A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 15:68-74, 2009
59. Desmedt C, Di Leo A, de Azambuja E, et al: Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol 29:1578-1586, 2011
60. Gucalp A, Traina TA: Triple-negative breast cancer: Role of the androgen receptor. Cancer J 16:62-65, 2010
61. Kreike B, van Kouwenhove M, Horlings H, et al: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9:R65, 2007
62. Rouzier R, Perou CM, Symmans WF, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685, 2005 (Pubitemid 41170290)
63. Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167, 2009
64. Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334, 2007 (Pubitemid 46698581)
65. Kennecke H, Yerushalmi R, Woods R, et al: Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271-3277, 2010
66. Kassam F, Enright K, Dent R, et al: Survival outcomes for patients with metastatic triple-negative breast cancer: Implications for clinical practice and trial design. Clin Breast Cancer 9:29-33, 2009
67. Giordano SH, Lin Y, Kuo Y, et al: Anthracycline (A) use among women with breast cancer (BC). J Clin Oncol 29:84s, 2011 (suppl; abstr 1019)
68. Cheang M, Chia SK, Tu D, et al: Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. J Clin Oncol 27:11s, 2009 (suppl; abtr 519)
69. Cheang M, Voduc D, Tu D, et al: The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial. J Clin Oncol 29:88s, 2011 (suppl; abstr 1032)
70. Di Leo A, Desmedt C, Bartlett JM, et al: Final results of a meta-analysis testing HER2 and topoisomerase IIalpha genes as predictors of incremental benefit from anthracyclines in breast cancer. J Clin Oncol 28:72s, 2010 (suppl; abstr 519)
71. Rocca A, Paradiso A, Sismondi P, et al: Benefit from CMF with or without anthracyclines in relation to biologic profiles in early breast cancer. J Clin Oncol 29:87s, 2011 (suppl; abstr 1031)
72. De Laurentiis M, Cancello G, D'Agostino D, et al: Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clin Oncol 26:44-53, 2008
73. ClinicalTrials.gov: BEATRICE study: A study of Avastin (bevacizumab) adjuvant therapy in triple negative breast cancer. http://clinicaltrials.gov/ ct2/show/NCT00528567
74. ClinicalTrials.gov: Maintenance treatment with capecitabine versus observation in breast cancer patients. http://clinicaltrials.gov/ct2/show/ NCT00130533
75. ClinicalTrials.gov: Efficacy of capecitabine metronomic chemotherapy to triple-negative breast cancer (SYSCBS-001). http://clinicaltrials.gov/ct2/show/ NCT01112826
76. ClinicalTrials.gov: A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). http:// clinicaltrials.gov/ct2/show/NCT00789581
77. ClinicalTrials.gov: Combination chemotherapy followed by docetaxel or ixabepilone in treating patients who have undergone surgery for nonmetastatic breast cancer. http://clinicaltrials.gov/ct2/show/NCT00630032
78. Perez EA, Patel T, Moreno-Aspitia A: Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat 121:261-271, 2010
79. Lindman H, Kellokumpu-Lehtinen P-L, Huovinen R, et al: Integration of capecitabine into anthracycline- and taxane-based adjuvant therapy for triple-negative early breast cancer: Final subgroup analysis of the FinXX Study. Cancer Res 70:24s, 2010 (suppl; abstr PD01-02)
80. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005 (Pubitemid 46224178)
81. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
82. Miles DW, Chan A, Dirix LY, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239-3247, 2010
83. Robert NJ, Dieras V, Glaspy J, et al: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 27:42s, 2009 (suppl; abstr 1005)
84. Brufsky A, Bondarenko IN, Smirnov V, et al: RIBBON-2: A randomized, double-blind, placebocontrolled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res 69:24s, 2009 (suppl; abstr 42)
85. O'Shaughnessy J, Dieras V, Glaspy J, et al: Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC). Cancer Res 69:24s, 2009 (suppl; abstr 207)
86. Viale G, Rotmensz N, Maisonneuve P, et al: Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: Prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 116:317-328, 2009
87. Carey LA, Rugo HS, Marcom PK, et al: TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 26:43s, 2008 (suppl; abstr 1009)
88. Baselga J, Gomez P, Awada A, et al: The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression-free survival (PFS) in metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II study (BALI-1). Ann Oncol 21:8s, 2010 (suppl; abstr 274)
89. Moyano JV, Evans JR, Chen F, et al: AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 116:261-270, 2006 (Pubitemid 43121811)
90. Albeck JG, Brugge JS: Uncovering a tumor suppressor for triple-negative breast cancers. Cell 144:638-640, 2011
91. Gronwald J, Byrski T, Huzarski T, et al: Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. J Clin Oncol 27:7s, 2009 (suppl; abstr 502)
92. Byrski T, Gronwald J, Huzarski T, et al: Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375-379, 2010
93. Byrski T, Huzarski T, Dent R, et al: Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 115:359-363, 2009
94. Silver DP, Richardson AL, Eklund AC, et al: Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145-1153, 2010
95. Wang Z, Hu X, Chen L, et al: Efficacy of gemcitabine and cisplatin (GP) as first-line combination therapy in patients with triple-negative metastatic breast cancer: Preliminary results report of a phase II trial. J Clin Oncol 28:138s, 2010 (suppl; abstr 1100)
96. Bhattacharyya GS, Basu S, Agarwal V, et al: Single institute phase II study of weekly cisplatinum and metronomic dosing of Endoxan and methotrexate in second line metastatic breast cancer triple-negative. Eur J Cancer Suppl 7:18, 2009 (abstr 41)
97. Alba E, Chacon J, Lluch A, et al: Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer: GEICAM 2006-03-A multicenter, randomized phase II study. J Clin Oncol 29:83s, 2011 (suppl; abstr 1015)
98. ClinicalTrials.gov: Triple negative breast cancer trial (TNT). http://www.clinicaltrial.gov/ct2/show/NCT00532727
99. ClinicalTrials.gov: Paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide in treating patients with breast cancer that can be removed by surgery. http://clinicaltrials.gov/ ct2/show/NCT00861705?term=NCT00861705&rank=1
100. Hoeijmakers JH: Genome maintenance mechanisms for preventing cancer. Nature 411:366-374, 2001
101. Ashworth A: A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26:3785-3790, 2008
102. DePinho RA, Polyak K: Cancer chromosomes in crisis. Nat Genet 36:932-934, 2004 (Pubitemid 39167483)
103. Gonzalez-Angulo AM, Timms KM, Liu S, et al: Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17:1082-1089, 2011
104. Turner NC, Reis-Filho JS, Russell AM, et al: BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26:2126-2132, 2007 (Pubitemid 46514749)
105. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4:814-819, 2004 (Pubitemid 39331153)
106. Patel AG, Sarkaria JN, Kaufmann SH: Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A 108:3406-3411, 2011
107. Vollebergh MA, Lips EH, Nederlof PM, et al: An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 22:1561-1570, 2010
108. Treszezamsky AD, Kachnic LA, Feng Z, et al: BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res 67:7078-7081, 2007 (Pubitemid 47206532)
109. Catteau A, Harris WH, Xu CF, et al: Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: Correlation with disease characteristics. Oncogene 18:1957-1965, 1999 (Pubitemid 29150082)
110. Esteller M, Silva JM, Dominguez G, et al: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92:564-569, 2000 (Pubitemid 30212318)
111. Magdinier F, Ribieras S, Lenoir GM, et al: Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region. Oncogene 17:3169-3176, 1998 (Pubitemid 29020812)
112. Rice JC, Ozcelik H, Maxeiner P, et al: Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 21:1761-1765, 2000
113. Grushko TA, Nwachukwu C, Charoenthammaraksa S, et al: Evaluation of BRCA1 inactivation by promoter methylation as a marker of triple-negative and basal-like breast cancers. J Clin Oncol 28:725s, 2010 (suppl; abstr 10510)
114. Ame JC, Spenlehauer C, de Murcia G: The PARP superfamily. Bioessays 26:882-893, 2004 (Pubitemid 39128102)
115. Bryant HE, Petermann E, Schultz N, et al: PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. Embo J 28:2601-2615, 2009
116. Bryant HE, Schultz N, Thomas HD, et al: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917, 2005 (Pubitemid 40559005)
117. Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921, 2005 (Pubitemid 40559006)
118. Iglehart JD, Silver DP: Synthetic lethality: A new direction in cancer-drug development. N Engl J Med 361:189-191, 2009
119. Tutt A, Robson M, Garber JE, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 376:235-244, 2010
120. Isakoff SJ, Overmoyer B, Tung NM, et al: A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 28:118s, 2010 (suppl; abstr 1019)
121. O'Shaughnessy J, Osborne C, Pippen JE, et al: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364:205-214, 2011
122. O'Shaughnessy J, Schwartzberg LS, Danso MA, et al: A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 29:81s, 2011 (suppl; abstr 1007)
123. Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134, 2009
124. Ljungman M: Targeting the DNA damage response in cancer. Chem Rev 109:2929-2950, 2009
125. Ji J, Lee MP, Kadota M, et al: Pharmacodynamic and pathway analysis of three presumed inhibitors of poly (ADP-ribose) polymerase: ABT-888, AZD2281, and BSI201. Proc Am Assoc Cancer Res 1:71, 2011 (abstr 4527)
126. Ossovskaya V, Lim C, Schools G, et al: Cell cycle effects of iniparib, a PARP inhibitor, in combination with gemcitabine and carboplatin in the MDA-MB-468(-) triple-negative breast cancer (TNBC) cell line. Cancer Res 70:24s, 2010 (suppl; abstr P5-06-09)